Lost password ?
Viral vectors can contribute to transform the lives of patients with severe diseases. Novasep, as a reliable CDMO, is committed and proud to be part of this rewarding challenge by offering its support to the clinical & commercial manufacture of your viral vectors.
For 20 years, Novasep has acquired experience in the development and manufacturing of biomolecules. Novasep’s specific know-how in a wide range of viral vectors includes:
… For gene therapy, immunotherapy, vaccination and other therapies.
More than 100 cGMP viral vector batches have been produced and released by Novasep over the last 5 years:
Novasep offers a global and integrated solution for viral vector manufacturing, including:
Our viral vector production services include upstream processing and downstream processing:
Click on this infographic to learn more about our viral vector commercial manufacturing offer
Novasep also has a fully dedicated plant for Fill & Finish (F&F) offering flexibility for standard & custom services. Our dedicated team can also provide stand-alone services.
The drug product release is handled by a Qualified Person at Novasep.
Watch the video below to learn more about our viral offer:
Our 2 viral vector manufacturing sites are ideally located at the heart of the Belgium’s largest biotech hub.
- Gosselies’s site is dedicated to clinical viral vector production:
- Seneffe’s site is dedicated to clinical and commercial viral vector production:
Inaugurated at the beginning of October 2018, Senrise-IV is dedicated to the commercial manufacture of your viral vectors:
Watch the video below to learn more about our Senrise-IV commercial production facility:
To support your project’s success, Novasep invests in a new commercial facility for aseptic Fill & Finish (F&F) operations: Senefill.
Novasep has a wide range of capabilities adapted to viral vector manufacturing. To learn more about our capabilities, download our viral vectors brochure!